The Microbiome as a
Therapeutic Target in
Inflammatory Bowel Disease.
The DFG Research Unit miTarget 5042 brings together an interdisciplinary group of experts in a coordinated programme to specifically study this single economically important and prototypically complex inflammatory disease.
News Show all
A report from Theresa Geese, doctoral researcher at IMIS in Kiel
I want to share my experience of a two-month scholarship at the Harvard T.H. Chan School of Public Health at the Huttenhower Lab in …read more
Events Show all
Patterns of gut microbiome dysbiosis in patients with inflammatory bowel diseases are inconsistent among published studies, probably owing to the heterogeneity of the disease and given the fact that patients enrolled in research studies are often treated and in remission. Therefore, more microbiome studies in “early” (incident) patients that are treatment-naïve and in high-risk individuals are needed. In addition, the microbiome field has to move from association to rather mechanistic studies in order to understand the actual functions and to also prove the associations that serve as hypotheses.
Institute of Clinical Molecular Biology
Prof. Dr. rer. nat. Andre Franke
Fon: +49 (0)431 500-15115
Doctoral qualification programme
Fon: +49 (0)431 500-15113